BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sochacka-Ćwikła A, Mączyński M, Regiec A. FDA-Approved Drugs for Hematological Malignancies-The Last Decade Review. Cancers (Basel) 2021;14:87. [PMID: 35008250 DOI: 10.3390/cancers14010087] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Sultonova RD, You SH, Choi Y, Kim SY, Lee WS, Seong J, Min JJ, Hong Y. The anticancer effect of PASylated calreticulin-targeting L-ASNase in solid tumor bearing mice with immunogenic cell death-inducing chemotherapy. Biochem Pharmacol 2023;210:115473. [PMID: 36863616 DOI: 10.1016/j.bcp.2023.115473] [Reference Citation Analysis]
2 de la Asunción Carlos S, Giménez E, Hernández-Boluda JC, Terol MJ, Albert E, López-Jiménez J, García-Gutiérrez V, Andreu R, García D, Fox ML, Remigia MJ, Amat P, Solano C, Navarro D. Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors. Br J Haematol 2023;200:e58-61. [PMID: 36652997 DOI: 10.1111/bjh.18655] [Reference Citation Analysis]
3 Jolles S, Giralt S, Kerre T, Lazarus HM, Mustafa SS, Ria R, Vinh DC. Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review. Front Oncol 2023;13:1098326. [PMID: 36824125 DOI: 10.3389/fonc.2023.1098326] [Reference Citation Analysis]
4 Mastalarz H, Mastalarz A, Wietrzyk J, Milczarek M, Kochel A, Regiec A. Studies on the Complexation of Platinum(II) by Some 4-Nitroisoxazoles and Testing the Cytotoxic Activity of the Resulting Complexes. Molecules 2023;28. [PMID: 36770951 DOI: 10.3390/molecules28031284] [Reference Citation Analysis]
5 Bou Malhab LJ, Alsafar H, Ibrahim S, Rahmani M. PROTACs: Walking through hematological malignancies. Front Pharmacol 2023;14:1086946. [PMID: 36909156 DOI: 10.3389/fphar.2023.1086946] [Reference Citation Analysis]
6 Tannoury M, Garnier D, Susin SA, Bauvois B. Current Status of Novel Agents for the Treatment of B Cell Malignancies: What's Coming Next? Cancers (Basel) 2022;14. [PMID: 36551511 DOI: 10.3390/cancers14246026] [Reference Citation Analysis]
7 Ghit A. Myelofibrosis treatment history and future prospects. Egypt J Intern Med 2022;34:81. [DOI: 10.1186/s43162-022-00169-x] [Reference Citation Analysis]
8 Izuegbuna OO. Polyphenols: Chemoprevention and therapeutic potentials in hematological malignancies. Front Nutr 2022;9. [DOI: 10.3389/fnut.2022.1008893] [Reference Citation Analysis]
9 Sochacka-Ćwikła A, Mączyński M, Czyżnikowska Ż, Wiatrak B, Jęśkowiak I, Czerski A, Regiec A. New Oxazolo[5,4-d]pyrimidines as Potential Anticancer Agents: Their Design, Synthesis, and In Vitro Biological Activity Research. Int J Mol Sci 2022;23:11694. [PMID: 36232997 DOI: 10.3390/ijms231911694] [Reference Citation Analysis]
10 Sochacka-Ćwikła A, Mączyński M, Regiec A. FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. Molecules 2022;27:2259. [PMID: 35408658 DOI: 10.3390/molecules27072259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Iannello A, Deaglio S, Vaisitti T. Novel Approaches for the Treatment of Patients with Richter's Syndrome. Curr Treat Options Oncol 2022. [PMID: 35294723 DOI: 10.1007/s11864-022-00973-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Shah PK, Shukla PK. Formation of bifunctional cross-linked products due to reaction of NAMI-A with DNA bases – a DFT study. Struct Chem. [DOI: 10.1007/s11224-022-01897-0] [Reference Citation Analysis]
13 Schmidts I, Haferlach T, Hoermann G. Precision Medicine in Therapy of Non-solid Cancer. Handbook of Experimental Pharmacology 2022. [DOI: 10.1007/164_2022_608] [Reference Citation Analysis]
14 Sidat PS, Jaber TMK, Vekariya SR, Mogal AM, Patel AM, Noolvi M. Anticancer Biological Profile of Some Heterocylic Moieties-Thiadiazole, Benzimidazole, Quinazoline, and Pyrimidine. Pharmacophore 2022;13:59-71. [DOI: 10.51847/rt6ve6gesu] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Crabtree JS, Miele L. Precision diagnostics in cancer: Predict, prevent, and personalize. Progress in Molecular Biology and Translational Science 2022. [DOI: 10.1016/bs.pmbts.2022.03.005] [Reference Citation Analysis]